Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study — Robin Kate Kelley (2021) | RDL Network
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Article 2021 en
Authors
RK
Robin Kate Kelley
BS
Bruno Sangro
WH
William Proctor Harris
Abstract
1 min read
All regimens were found to be tolerable and clinically active; however, the T300 + D regimen demonstrated the most encouraging benefit-risk profile. The unique pharmacodynamic activity and association with ORR of the T300 + D regimen further support its continued evaluation in HCC.
Robin Kate Kelley, Bruno Sangro, William Proctor Harris, Masafumi Ikeda, Takuji Okusaka, Yoon‐Koo Kang, Shukui Qin, Wai Meng David Tai, Ho Yeong Lim, Thomas Yau, Wei Peng Yong, Ann‐Lii Cheng, Antonio Gasbarrini, Filippo de Braud, Jordi Bruix, Mitesh J. Borad, Philip He, Alejandra Negro, Masatoshi Kudo, Ghassan K. Abou‐Alfa
Ghassan K. Abou‐Alfa, Stephen L. Chan, Masatoshi Kudo, George Lau, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon‐Koo Kang, Tu Van Dao, Enrico N. De Toni, Lorenza Rimassa, В. В. Бредер, Alexander Vasilyev, Alexandra Heurgué, Vincent C. Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Philip He, Alejandra Negro, Bruno Sangro
B. Sangro, Stephen L. Chan, Robin Kate Kelley, George Lau, Masatoshi Kudo, Wattana Sukeepaisarnjaroen, M. Yarchoan, Enrico N. De Toni, J. Furuse, Yoon‐Koo Kang, Peter R. Galle, Lorenza Rimassa, Alexandra Heurgué, Vincent C. Tam, Tu Van Dao, S.C. Thungappa, В. В. Бредер, Y. Ostapenko, María Reig, M. Makowsky, Michael J. Paskow, Charu Gupta, ,
Ho Yeong Lim, Jeong Heo, Tae‐You Kim, Wai Meng David Tai, Yoon‐Koo Kang, George Lau, Masatoshi Kudo, Won Young Tak, Magdalena Watras, S. Ali, Alejandra Negro, Ghassan K. Abou‐Alfa, Robin Kate Kelley
Discussion(0)
No comments yet. Be the first to comment.